Scientists know how to make lung cancer prevention more effective
09 January 2013, 16:12
Testing of drugs for the prevention of lung cancer requires a considerable amount of time. The results have to wait five, ten or even fifteen years. Unfortunately, at the moment there is no way that I could quickly identify the effectiveness of a drug. Researchers at the University of Colorado Cancer Center in Denver offer new ways to test drugs that could significantly reduce not only the time required to pass the test, but also to reduce the number of patients that are utilized in the tests.
Experts say that chemoprophylaxis (reception of specific anti-TB drugs by healthy people who are at particular risk of developing tuberculosis, in order to prevent their disease) is an important approach in the prevention of lung cancer.
"If we could find a surrogate (en) end point of death from this terrible disease like lung cancer , it would be much easier of trials, as well as significantly reduce the time of their conduct" - says lead author of the study, Professor Fred Hirsch.
The original purpose of the study was to detect specific miRNAs, the level of severity which can predict whether a patient's body react to chemoprophylaxis. Depending on what level of expression of microRNA find experts, and so further research will be built: the scientists will be able to test the drug only on those patients, whose result will be the most potentially successful. MicroRNAs - segments of genetic material that can be used as diagnostic indicators of lung cancer.
The expression of miRNA 34c changes occur six months after treatment. For those patients who have the effect of drug action was seen six months later, the expression of miRNA 34c was lower among those study participants who did not reveal any changes in the expression of miRNA 34c remained unchanged.
"Instead of waiting for the result of fifteen years of research, we could find out if chemoprophylaxis is effective using a particular medication within six months after treatment. It would be possible to accelerate the pace of testing that eventually would lead to a more rapid development of new drugs to the market ", - says Dr. Hirsch.
Dr. Hirsch says that this finding needs further research and testing, but the ability to "predict" the results using microRNA-34c can make a significant contribution to the quality of treatment of patients with lung cancer.
CA-15-3 is an antigen of the membrane of cells of metastatic breast carcinoma. In healthy individuals, it can be determined on the epithelium of secreting cells and in secrets. CA-15-3 has a sufficiently high specificity for carcinoma of the breast...
The latest research relating Учёные знают как сделать профилактику рака лёгких эффективнее
The development of the CimaVax-EGF vaccine by specialists of the Center for Molecular Immunology in Havana lasted 25 years. This drug is an analogue of epidermal growth factor (EGF), necessary for the growth and spread of cancer cells.